Healthy ParticipantsPhase 1NCT07811999
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections
A Phase 1 study testing Romosozumab in people with Healthy Participants, run by Amgen at 2 sites in 2 countries.
Trial summary
The primary objective of this trial is to evaluate the relative bioavailability of romosozumab administered as a single 2.34 mL subcutaneous (SC) injection from a prefilled syringe (PFS) or 2 x 1.17 mL SC injections from PFS in healthy participants. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Participants
- What is being tested?
- Romosozumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 308 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 22 Sep 2026to 14 Jan 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy adults, male or female, 18 to 60 years of age.
- Able and willing to provide written informed consent before any study procedures.
- Body weight between 45.0 kg and 95.0 kg (inclusive).
- Women must not be able to become pregnant (for example, postmenopausal or permanently sterile, as defined by the protocol).
- Men who can father a child must agree to use the required contraception during the study and for 3 months after the study drug dose.
- Willing and able to take daily calcium (500 to 2,000 mg elemental calcium) and vitamin D (at least 400 IU) supplements from Day 1 through the end of the study.
Who cannot join
- Any clinically significant medical condition or abnormal finding that, in the opinion of the study doctor, could make participation unsafe or interfere with the study or its results.
- Clinically significant abnormalities on medical history, physical examination, vital signs, electrocardiogram (ECG), or laboratory tests, including suspected Gilbert syndrome.
- History or current signs or symptoms of significant cardiovascular disease, including heart attack, heart failure, congenital heart disease, cardiomyopathy, valve disease, angina, coronary revascularization, stroke, transient ischemic attack, or peripheral revascularization.
- Clinically significant abnormal heart rhythm or conduction disorder, including clinically significant ECG abnormalities.
- QT interval corrected for heart rate (QTcF) greater than 450 milliseconds for men or greater than 470 milliseconds for women, or a history of long QT syndrome.
- Second- or third-degree atrioventricular (AV) block.
Show all 49Show fewer
- Systolic blood pressure greater than 140 millimeters of mercury (mmHg) or less than 90 mmHg, diastolic blood pressure greater than 90 mmHg or less than 50 mmHg, or pulse rate greater than 100 beats per minute or less than 40 beats per minute at screening or check-in.
- Deep vein thrombosis or pulmonary embolism within 3 months before screening.
- History of osteoporosis, vertebral fracture, or a fragility fracture of the wrist, upper arm, hip, or pelvis after 50 years of age.
- History of metabolic bone disease, including conditions such as Paget disease, osteomalacia, osteogenesis imperfecta, osteopetrosis, sclerosteosis, ankylosing spondylitis, rheumatoid arthritis, Cushing disease, hyperprolactinemia, or malabsorption syndrome.
- History of osteonecrosis of the jaw.
- Bone fracture within 6 months before screening.
- Vitamin D level below 20 nanograms per milliliter (ng/mL) at screening (participants may be treated and retested before enrollment).
- Current hyperparathyroidism or hypoparathyroidism.
- Kidney function below study requirements (estimated glomerular filtration rate less than 60 mL/min/1.73 m^2).
- Low or high blood calcium levels that do not meet study requirements.
- Liver blood test results (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) above the normal range.
- History of hyperthyroidism or hypothyroidism unless on stable treatment for at least 6 months with normal thyroid function tests.
- History of hearing loss caused by excessive bone growth compressing the eighth cranial nerve.
- Positive test for human immunodeficiency virus (HIV).
- Active hepatitis B or hepatitis C infection.
- Cancer within the past 5 years, except non-melanoma skin cancer or cervical or breast ductal carcinoma in situ.
- History of solid organ or bone marrow transplantation.
- History of allergy or hypersensitivity to romosozumab, its ingredients, other biologic medicines, or medicines derived from mammalian cells.
- Previous use of medications affecting bone metabolism that are not allowed by the protocol, including:
- Any intravenous or oral bisphosphonate.
- Fluoride for osteoporosis within 24 months before screening.
- Denosumab or cathepsin K inhibitors within 18 months before screening.
- Parathyroid hormone or strontium within 12 months before screening.
- Calcitonin, selective estrogen receptor modulators, or tibolone within 3 months before screening.
- Systemic corticosteroids (5 mg or more prednisone equivalent daily for more than 10 days) within 3 months before screening.
- Use of prescription or over-the-counter medications within 30 days or 5 half-lives (whichever is longer) before check-in, unless approved by the study doctor. Acetaminophen up to 2 g/day is permitted. Stable hormone replacement therapy is allowed if unchanged for at least 3 months before dosing and throughout the study.
- Use of herbal medicines, vitamins (other than study-required calcium and vitamin D), or dietary supplements within 30 days before enrollment unless approved by the study doctor.
- Currently participating in another clinical study, receiving another investigational treatment, or participation in another investigational drug or device study within the previous 90 days or 5 half-lives (whichever is longer).
- Previous participation in this study or previous exposure to a sclerostin antibody.
- History of alcohol abuse or regular alcohol intake greater than 14 units per week within the year before check-in.
- Alcohol use within 48 hours before check-in or unwillingness to comply with study alcohol restrictions.
- Positive alcohol test at check-in.
- Positive drug screen for illicit drugs, including cannabis, at screening or check-in.
- History of illicit drug use within 6 months before screening.
- Unwilling to avoid illicit drug use, including cannabis, throughout the study.
- Smoking more than 10 cigarettes per day or equivalent nicotine use within 1 month before check-in, or unwillingness to comply with study tobacco restrictions.
- Consumption of foods or drinks containing poppy seeds within 7 days before check-in.
- Positive pregnancy test at screening or check-in.
- Pregnant, breastfeeding, or planning to breastfeed during the study or within 3 months after receiving the study drug.
- Receipt of blood products within 2 months before check-in.
- Blood donation within 3 months before screening, plasma donation within 2 weeks before screening, or platelet donation within 6 weeks before screening.
- Poor veins that would make repeated blood sampling difficult.
- Any other reason that, in the opinion of the study doctor, would make participation unsafe or inappropriate.
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
United States1 site, 1 recruiting
- Recruiting
QPS Miami
Miami, Florida, 33143
United Kingdom1 site, 1 recruiting
- Recruiting
Fortrea Clinical Research Unit Limited - Leeds
Leeds, LDS, LS11 9EH
About this study
Official title: A Phase 1, Open-label, Randomized, Parallel Group Study to Evaluate the Relative Bioavailability of Romosozumab (AMG 785) 210 mg Administered as a Single SC Injection or 2 SC Injections in Healthy Participants
The primary objective of this trial is to evaluate the relative bioavailability of romosozumab administered as a single 2.34 mL subcutaneous (SC) injection from a prefilled syringe (PFS) or 2 x 1.17 mL SC injections from PFS in healthy participants.
- Conditions
- Healthy Participants
- Being tested
- Romosozumab
- Keywords
- AMG 785, Healthy Participants, Romosozumab
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RomosozumabDrug
Also called AMG 785, Evenity®
Romosozumab will be administered via SC injection using a PFS.
| Study group | Role | What they receive |
|---|---|---|
| Romosozumab Test Arm | Experimental | Participants will receive a single SC injection of romosozumab (test) administered using a PFS. Receives: Drug: Romosozumab |
| Romosozumab Reference Arm | Active comparator | Participants will receive two SC injections of romosozumab (reference) administered using a PFS. Receives: Drug: Romosozumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of romosozumab
Measured: Up to Day 85
Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) of romosozumab
Measured: Up to Day 85
Maximum Observed Serum Concentration (Cmax) of romosozumab
Measured: Up to Day 85
Secondary outcomes (2)
Number of Participants Who Experienced Treatment-Emergent Adverse Events and Serious Adverse Events
Measured: Up to Day 85
Number of Participants Who Developed Anti-romosozumab Antibodies
Measured: Up to Day 85
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2026
- Study start22 Sep 2026
- Primary completion14 Jan 2027 (estimated)
- Study completion14 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy ParticipantsStudies of the same condition, open and under way.
- More trials run by AmgenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 308 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Amgen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- MD, Study director, Amgen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07811999
- Sponsor's protocol ID
- 20250008
- Status last verified
- Oct 2026
- First submitted
- 4 Sep 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Open-label, Randomized, Parallel Group Study to Evaluate the Relative Bioavailability of Romosozumab (AMG 785) 210 mg Administered as a Single SC Injection or 2 SC Injections in Healthy Participants
- ClinicalTrials.gov ID
- NCT07811999
- Acronym / sponsor ID
- 20250008
- Conditions
- Healthy Participants
- Keywords
- AMG 785, Healthy Participants, Romosozumab
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 308 participants (estimated)
- Lead sponsor
- AmgenIndustry (pharma, biotech, devices)
- Study start
- 22 Sep 2026 (actual)
- Primary completion
- 14 Jan 2027 (estimated)
- Study completion
- 14 Jan 2027 (estimated)
- First posted
- 10 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this trial is to evaluate the relative bioavailability of romosozumab administered as a single 2.34 mL subcutaneous (SC) injection from a prefilled syringe (PFS) or 2 x 1.17 mL SC injections from PFS in healthy participants.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Romosozumab Test Arm | Experimental | Drug: RomosozumabParticipants will receive a single SC injection of romosozumab (test) administered using a PFS. |
| Romosozumab Reference Arm | Active comparator | Drug: RomosozumabParticipants will receive two SC injections of romosozumab (reference) administered using a PFS. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Healthy adults, male or female, 18 to 60 years of age.
- Able and willing to provide written informed consent before any study procedures.
- Body weight between 45.0 kg and 95.0 kg (inclusive).
- Women must not be able to become pregnant (for example, postmenopausal or permanently sterile, as defined by the protocol).
- Men who can father a child must agree to use the required contraception during the study and for 3 months after the study drug dose.
Key exclusion criteria (49 listed)
- Any clinically significant medical condition or abnormal finding that, in the opinion of the study doctor, could make participation unsafe or interfere with the study or its results.
- Clinically significant abnormalities on medical history, physical examination, vital signs, electrocardiogram (ECG), or laboratory tests, including suspected Gilbert syndrome.
- History or current signs or symptoms of significant cardiovascular disease, including heart attack, heart failure, congenital heart disease, cardiomyopathy, valve disease, angina, coronary revascularization, stroke, transient ischemic attack, or peripheral revascularization.
- Clinically significant abnormal heart rhythm or conduction disorder, including clinically significant ECG abnormalities.
- QT interval corrected for heart rate (QTcF) greater than 450 milliseconds for men or greater than 470 milliseconds for women, or a history of long QT syndrome.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RomosozumabAlso: AMG 785, Evenity®Romosozumab will be administered via SC injection using a PFS. | Drug | Romosozumab Reference Arm, Romosozumab Test Arm |
Primary outcome
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of romosozumab
Time frame: Up to Day 85
Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) of romosozumab
Time frame: Up to Day 85
Maximum Observed Serum Concentration (Cmax) of romosozumab
Time frame: Up to Day 85
2 secondary outcomes
Number of Participants Who Experienced Treatment-Emergent Adverse Events and Serious Adverse Events
Time frame: Up to Day 85
Number of Participants Who Developed Anti-romosozumab Antibodies
Time frame: Up to Day 85
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- AmgenTrials clinical trials websiteLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Related trials for Healthy Participants
RecruitingObservational study
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
Mood Disorders, Anxiety Disorders
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
RecruitingPhase 1
A Single Ascending Dose Study of DTI-117 Given Intramuscularly in Healthy Participants.
Healthy Adult
RecruitingObservational study
Collection of Lung Fluid and Tissue Samples for Research
Leukocyte Disorders, Respiratory Tract Diseases
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
MD study director
Amgen
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Romosozumab in people with Healthy Participants, run by Amgen at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 49 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amgen Call Center (866-572-6436, medinfo@amgen.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of romosozumab (time frame: Up to Day 85). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.